We are working on a Johns Hopkins-approved research study about Amyotrophic Lateral Sclerosis (ALS). This research is being done to examine whether the hallucinogenic drug, psilocybin, given under supportive conditions, is safe and helpful for improving mood, quality of life, hopelessness, and function in people with ALS. The study’s principal investigators are Ambereen K. Mehta, MD, MPH and Albert Garcia-Romeu, PhD and the study protocol number is IRB00408938.
  

The study will involve about 36 hours (3 to 5 in-person visits with potential for others to be done remotely) with the study team over roughly 8 months, including medical screening, blood draws, interviews, two psilocybin dosing sessions, and collecting questionnaire responses before, during, and after the study intervention. Participants will be compensated up to $730 for completion of all steps. Because the study involves repeated onsite visits to our laboratory in Baltimore, MD, we are prioritizing individuals who live within reasonable travel distance of Baltimore (e.g., < 3 hours away).
 

You May Be Eligible if You...

• Have been diagnosed with ALS
• Are at least 18 years old
• Have feelings of despair and/or sadness
• Have a care partner willing to help you during the study
• Are able to swallow pills

* There are additional eligibility criteria

Participants will be compensated up to $730 for completion of all steps.

Before enrolling people in this study, we need to ask a few questions about your current and past medical history to determine if you are eligible. Your taking part in this screening is completely voluntary and will not impact the care you receive.

Please click "Next" below to complete a screening survey for this study.